Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NICE bid !!
It was a nice week this week....
Check out the NEW PR firm that CRYO hired... very impressive firm and chairman!
tallgrass public relations- http://www.tallgrasspr.com/
and the link to the Chairman of TallGrass PR Firm very impressive https://en.wikipedia.org/wiki/Jeffrey_W._Hayzlett
GREAT point les, that defiantly puts it in perspective !!
agreed !! btw- did you notice they have a PR firm now...
Media ContactSeth Menacker
TallGrass Public Relations [color=red][/color]
(201) 638-7561
seth.menacker@tallgrasspr.com
I looked them up and they appear to be a GREAT firm !!
wow, finally touched 1.00 again...
https://www.otcmarkets.com/stock/CRYO/news/story?e&id=1046423
EATONTOWN, N.J., April 05, 2018 (GLOBE NEWSWIRE) -- American CryoStem Corporation (OTC:CRYO), a leading strategic application developer, marketer, global licensor of patented adipose tissue-based cellular technologies, for the Regenerative and Personalized Medicine industries, today announced further expansion of its global laboratory and cellular technology footprint by entering into an agreement to license its ATGRAFT™ and ATCELL adipose tissue (fat) processing and storage technologies with Cryoviva (Thailand) Ltd., a Bangkok, Thailand based Cord Blood processing and storage facility. Cryoviva, Thailand, currently offers collection, processing and storage of Cord Blood derived biologics to patients throughout Thailand and South East Asia.
American CryoStem has licensed to Cryoviva (Thailand) Ltd., established in 2007, the rights to utilize the Company's Standard Operating Procedures (SOP's) to create and market the Company's ATGRAFT™ tissue storage service and ATCELL™ adipose derived stem cell processing and storage services in Thailand. The financial terms generally, call for the payment of certain training fees and, a percentage of the gross revenue subject to annual minimum payments generated from our products. Additionally, the Agreement calls for the purchase of CRYO consumable products required for ATGRAFT and ATCELL sample processing including CRYO's ACSelerate™ non-DMSO cryogenic tissue storage media, transportation media, Cellect™ tissue collection kit, and ACSelerate – Max™ cell culture medium.
John Arnone, CEO of American CryoStem commented, "We are pleased to announce our fourth international licensing agreement in the Asian market for our collect-process-store-retrieve, adipose tissue and cellular based platform with an established company of Cryoviva’s caliber and global presence. This license furthers our corporate mission to establish a global network of laboratories operating under a standardized platform utilizing our patented consumables for processing." Arnone further commented, "Working with Cryoviva in the Thailand market presents an exciting opportunity for our technology to provide the foundational tissue processing and cryopreservation support platform required for the advancement of the rapidly expanding Regenerative/Personalized Medicine and Cell Therapy market. Further, we also gain another experienced affiliate as we work our way through US FDA and continue to develop adipose derived cellular applications.”
Anthony Dudzinski, COO of American CryoStem, added, "American CryoStem's entry into the Thailand market represents an extension of the Company's ongoing licensing and product distribution efforts into new markets. This licensing agreement allows our partners to grow and establish a foundation in the adipose tissue derived cellular therapy market, while also providing the opportunity to leverage our full multi-phase adipose tissue and stem cell solution. This includes expansion, differentiation and return methods, as well as the materials to create a true “point of care” platform. As Thailand and the greater Asian regenerative market continue to grow, we expect increasing distribution of our products and services," said Dudzinski.
About American CryoStem Corporation
American CryoStem Corporation (OTC:CRYO) founded in 2008, is a biotechnology pioneer, standardizing adipose tissue (fat) derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The Company operates a state-of-art, FDA-registered, laboratory in New Jersey and licensed laboratories in Hong Kong, Bangkok, Thailand, China and Tokyo, Japan, which operate on our proprietary platform, dedicated to the collection, processing, bio-banking, culturing and differentiation of adipose tissue and adipose derived stem cells (ADSCs) for current or future use in regenerative medicine. CRYO maintains a strategic portfolio of intellectual property (IP) that surrounds our proprietary technology which supports a growing pipeline of stem cell applications and biologic products. We are leveraging our platform and a developed product portfolio to create a global footprint of licensed laboratory affiliates, domestic and international physicians networks and research organizations who purchase tissue collection, processing and storage consumables from CRYO. Our laboratory stem cell bank/line products are characterized adult human Mesenchymal Stem Cell (MSC's) derived from adipose tissue that work in conjunction with our patented (non-animal) medium lines. The Company's R&D efforts are focused on university and private collaborations to discover, develop and commercialize ADSC therapies by utilizing our standardized collection-processing-storage methodology and laboratory products combined with synergistic technologies to create jointly developed regenerative medicine applications and intellectual property.
About Cryoviva
Cryoviva (Thailand) Ltd. was established in 2007 with the cooperation of leading companies in the world such as Indorama Ventures Public Company Limited Thailand, Chelyabins International India and Arjun Corp India, a company specializing in stem cells. Cryoviva has been ISO 9001: 2008 Quality Management System and Laboratory Management System According to ISO 15189: 2007 from Bure Veritas Certification, UKAS Certified Body and is also the only cord blood bank certified by AABB. Cryoviva (Thailand) Co., Ltd. is the only stem cell bank that has been approved by the Board of Investment (BOI or Thailand Board of Investment). Cryoviva (Thailand) Co., Ltd. was awarded the "Thailand Stem Cells of the Year," 2016 and 2017.
Media ContactSeth Menacker
TallGrass Public Relations
(201) 638-7561
seth.menacker@tallgrasspr.com
Source: American CryoStem Corporation
© 2018 GlobeNewswire, Inc.
Wrong board wwj !!
yes it was !! lets hope it gets thinner on the way up !!
yes it has.... and you might be correct...
Wow, nice bid on CRYO ...
thank you !!
thank you for the update... would you mind sharing the twitter link?
funny,
PLEASE give us your thoughts on PDPR..
noclue,
do you still know people working there? are they working on anything to come to market?
you can still trade this stock as its been up to .04 and .045 and back down to .01s...
PLEASE answer this for me... If it's such a bad company as you state, why are you here? smh...
nice find, you know someone ihub people will try to argue nasdaq is lying...lol
wow, so much dumping today !! LMAO !!
another day of NICE volume !!
funny he starred the WRONG area !!! LMAO !!
25k today and still nothing from the company !! i guess they'll never come out with anything.. SELL the shell !!
funny when they bash this company than accuse of illegal transactions..lol
i agree shortorlong !!
aww.. GOOD point !! i missed that ... ty bighdaddie...
Wow, very nice volume today...
Bids starting to line up..
I'm guessing we may have seen the BOTTOM for MCIG !!
FINALLY someone took out the .62s !! onward and upward !! will we see .75 in the near future ??
i'll take that bet... pick your target date in May !!
Now thats funny....008 .... It wont happen !!
and even funnier, someone took all those shares and it's still back above .01 !!
Wow, it did !!
BIG wall up of 3.7 million... dont think its going to dip past that !!
for some reason the news story doesn't show up on my tdameritrade?? anyone else with this problem??
This is the most exciting part to me of the PR..." Management believes the value of the Company's platform and products is significantly enhanced with each grant of claims within our existing patent portfolio which we believe will ultimately enhance shareholder value. We will be following up the Notice of Allowance with both Continuation and a Continuation in Part filings to further protect our intellectual property and investment into development of improvements and new methodologies." [color=red][/color]
agreed biotechfunder !! imo undervalued company ...
EATONTOWN, NJ / ACCESSWIRE / March 27, 2018 / American CryoStem Corporation (OTC PINK: CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced receiving a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. patent application 13/702.304 related to methods of Collection, Processing, Cryogenic Storage and Distribution of a Biologic Sample.
The Business Method patent was developed to protect our, core technology platform; collect, process, store and return of stem cell samples to physicians, "point of care”. Additionally, the Claims cover the Company's developed methods and materials including its CELLECT® collection kits, transport mediums, cryopreservation of biologics and proprietary shipping methods designed for both autologous and non-autologous biologic samples.
John Arnone, CEO stated, "We are pleased that we have achieved this milestone with the issuance of these allowed claims. Since our inception we have been focused on efficient methods to advance Personalized Medicine. This is the culmination of many years of laboratory work and significant investment in our research to streamline the platform. He continued, "We believe that this is a major development for the protection of our technology, as the industry advances others may use the complete or select modules of the platform to deliver their biologic products and cellular treatments."
Management believes the value of the Company's platform and products is significantly enhanced with each grant of claims within our existing patent portfolio which we believe will ultimately enhance shareholder value. We will be following up the Notice of Allowance with both Continuation and a Continuation in Part filings to further protect our intellectual property and investment into development of improvements and new methodologies."
About American CryoStem Corporation
American CryoStem Corporation (OTC PINK: CRYO); founded in 2008, is a biotechnology pioneer, standardizing adipose tissue (fat) derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The Company operates a state-of-art, FDA-registered, laboratory in New Jersey and licensed laboratories in Hong Kong, Bangkok, Thailand, China and Tokyo, Japan, which operate on our proprietary platform, dedicated to the collection, processing, bio-banking, culturing and differentiation of adipose tissue and adipose derived stem cells (ADSCs) for current or future use in regenerative medicine. CRYO maintains a strategic portfolio of intellectual property (IP) that surrounds our proprietary technology which supports a growing pipeline of stem cell applications and biologic products. We are leveraging our platform and a developed product portfolio to create a global footprint of licensed laboratory affiliates, domestic physicians networks and research organizations who purchase tissue collection, processing and storage consumables from CRYO. Our laboratory stem cell bank/line products are characterized adult human Mesenchymal Stem Cell (MSC's) derived from adipose tissue that work in conjunction with our 13 patented (non-animal) medium lines. The Company's R&D efforts are focused on university and private collaborations to discover, develop and commercialize ADSC therapies by utilizing our standardized collection-processing-storage methodology and laboratory products combined with synergistic technologies to create jointly developed regenerative medicine applications and intellectual property.
For further detailed Corporate or Regenerative Medicine information please visit:
www.americancryostem.com, request by email at info@americancryostem.com or phone 732-747-1007
This press release may contain forward-looking statements, including information about management's view of American CryoStem Corporation's ("the Company") future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.
SOURCE: American CryoStem Corporation
© Copyright 2018 ACCESSWIRE. All Rights Reserved.
MCIG and OMHE short interest are down...hmmm what could that mean ??
very true, if people would READ the PR's from CRYO they'd understand what is going on w/ the company ..smh at people who just post random things w/ NO KNOWLEDGE of whats is going on in and with the CRYO !!
apparently Shorts have covered and week hands have sold, if good news is released this will FLY HIGH !!